54 billion won ⟵ 3.7 billion won in four years

ARB + CCB + statin combination prescription amount 54 billion won ⟵15.7 billion won in 2019 last year

ARB+Statin declined since 2021, ↓ 7% of last year's prescription

In the high blood pressure and hyperlipidemia complex market, the pace of generational replacement between the second and third complexes is accelerating.

 

The size of outpatient prescriptions for the third-party complex of the ARB+CCB+statin combination has tripled in the past three years, expanding to the market of more than 50 billion won a year.

 

The ARB+statin combination's second-generation complex market has been on the decline since its peak in 2021.

 

In the case of last year, the market size fell below 90 billion won, down 7% year-on-year.

 

◆ Three-drug complex last year's prescription amount was 54 billion won, 3.4 times in three years According to UBIST, a pharmaceutical market research institute on the 25th, the outpatient prescription amount of the three-drug combination of hypertension and hyperlipidemia last year was 54 billion won.

 

This market has exploded recently.

 

The market size expanded from 3.7 billion won in 2018 to 15.7 billion won in 2019, 34.9 billion won in 2020, and 50.8 billion won in 2021.

 

In other words, the size of the market has expanded 3.4 times in the past three years.

 

The market was formed in October 2017 when Hanmi Pharmaceutical launched "AmosartanQ" in a combination of Amlodipine + Losartan + Rosuvastatin.

 

The following year, Ildong Pharmaceutical, Jeil Pharmaceutical, Daewon Pharmaceutical, Celltrion Pharmaceutical, and Samjin Pharmaceutical introduced the third-generation complex to the market.

 

In 2019, Yuhan, Hana, Daewoong, Ahngook Pharmaceutical, and HK inno.N launched their products, and in 2020, Boryeong, Myungmoon, Kyungdong Pharmaceutical, and Unimmed Pharmaceutical launched their products.

 

Most of them are products that have improved their second-order composite.

 

The market leader is Boryung Dukaro.

 

Dukaro made a soft landing in the market with a prescription performance of 6.4 billion won in the first year of its launch in 2020.

 

In 2021, it doubled to 12.7 billion won.

 

At the same time, it surpassed Hanmi Pharmaceutical's AmosartanQ, which is the No.

 

1 product in the existing market, and took the lead in the market.

 

Last year, prescription performance increased further to 14.1 billion won.

 

Hanmi Pharmaceutical's "AmosartanQ" steadily increased to 2.7 billion won in 2018, 6.8 billion won in 2019, 10.5 billion won in 2020, and 11.4 billion won in 2021.

 

Still, its growth seems to have slowed to 11.3 billion won last year.

 

In addition, Daewoong Pharmaceutical's Ollomax (8.7 billion won), Ildong Pharmaceutical's Telostop Plus (4 billion won), Yuhan Duowell A (2.8 billion won), and HKinno.N Exone-R (2.8 billion won) produced more than 2 billion won last year.

 

Since the success of the third-party complex, competition for the fourth-party complex is also in full swing.

 

Likewise, Hanmi Pharmaceutical first pioneered the market and other companies entered the competition with drugs from the same combination of ingredients.

 

Hanmi Pharmaceutical was approved for Amozaltan XQ in November 2020.

 

The prescription amount of Amozaltan XQ increased 2.7 times from 2.3 billion won in 2021 to 6.4 billion won last year.

 

Following Hanmi Pharmaceutical's Amozaltan XQ, Yuhan Duowell A Plus, GC Pharma Rozetelpine, Jeil Pharmaceutical's Telmican-Q, and Chong Kun Dang Nuvorozet were approved one after another.

 

The pharmaceutical industry predicts that competition for the fourth-generation complex will take place in earnest this year.

 

◆2nd Compound Market Decreases to Less than 90 Billion won As the 3rd and 4th composite markets grow explosively, the pace of generational replacement with the existing 2nd composite is also accelerating.

 

Last year, the market size of the ARB+Statin combination's second-generation complex was 89.6 billion won, down 7% from 2021.

 

The second complex market has steadily expanded to 86.9 billion won in 2018, 90.4 billion won in 2019, 94.5 billion won in 2020, and 96.5 billion won in 2021, but it has been reduced for the first time last year.

 

Most of the major products are also on the decline.

 

Yuhan Duowell's prescription amount increased to 20 billion won in 2018 but has steadily decreased since then.

 

Last year, prescriptions fell to 16.5 billion won.

 

Hanmi Pharmaceutical's Rovelito also peaked at 22.7 billion won in 2018 and steadily decreased to 15 billion won last year.

 

JW Pharmaceutical's Livaro V, LG Chem's Rovatitan, and Ildong Telostop also saw their prescriptions fall more than 10% year-on-year last year.

 

The prescription performance of Akarb and Tuvero in Boryung increased.

 

Akarb recorded a prescription amount of 7.4 billion won last year.

 

It increased by 14% compared to 6.5 billion won in 2020.

 

Tuvero, which combines fimasartan with Rosuvastatin, increased slightly from 6.4 billion won to 6.5 billion won.